



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated October 18, 2017

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Receipt of approval from US FDA for ANDA filed by USpharma Windlas, LLC -Reg.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by USpharma Windlas, LLC through its subsidiaries, First time US Generics LLC and Liberty Pharma, Inc. for Prasugrel Tablet 5mg and 10 mg. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Effient Tablet 5 mg and 10 mg of Eli Lilly and Company.


Granules India Limited through its wholly owned subsidiary, Granules Pharmaceuticals, Inc. had acquired the exclusive rights from USpharma Windlas, LLC in June 2016 to market and distribute its four products in USA, including Prasugrel. Granules Pharmaceuticals, Inc. intend to Launch Prasugrel.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For **GRANULES INDIA LIMITED**



CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)